LIMNWHIGH SIGNALFINANCIAL10-Q

LIMNW experienced a dramatic deterioration in financial performance with net losses increasing 851% while successfully resolving a major equity financing issue and Nasdaq compliance matter.

The company's net loss exploded from $214K to $2.0M quarter-over-quarter, representing an 851% increase that signals severe operational challenges despite increased R&D spending. However, the successful issuance of $7.2M in shares to underwriters and resolution of the Nasdaq deficiency letter provides critical capital and removes immediate regulatory risks.

Comparing 2025-11-14 vs 2025-10-06View on EDGAR →
FINANCIAL ANALYSIS

The company shows a tale of two narratives - dramatically worsening operations with net losses increasing 851% and operating losses growing 51%, but a much-improved balance sheet following equity financing. Stockholders' equity improved 81% from deeply negative territory, while current liabilities dropped 73% and total assets declined 30% primarily due to cash usage. The financial picture suggests the company burned through significant cash while securing new equity capital, leaving it in a precarious operational position despite temporary balance sheet relief.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-851.1%
-$214K-$2.0M

Net income declined 851.1% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
+81.3%
-$8.8M-$1.6M

Equity base grew 81.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-72.8%
$10.5M$2.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-72.1%
$10.7M$3.0M

Liabilities reduced 72.1% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
-50.7%
-$1.4M-$2.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
-32.5%
$1.8M$1.2M

Current assets declined 32.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-29.7%
$1.9M$1.3M

Total assets contracted 29.7% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
+15.3%
$2.3M$2.7M

R&D investment increased 15.3% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2025-11-14
PRIOR — 2025-10-06
ADDED
On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $ 7,245,000 .
The deficiency letter had no immediate effect on the listing of the Company s common stock, and its common stock continued to trade on Nasdaq under the symbol LIMN .
On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.
As of September 30, 2025, the Company had $ 724,502 of cash in its bank accounts.
The Company has an accumulated deficit of $ 30,702,806 as of September 30, 2025.
+7 more — sign up free →
REMOVED
Employer Identification No.) 6 Centerpointe Drive #625 , La Palma , CA 90623 (Address of principal executive offices, including zip code) ( 213 ) 273-5453 (Registrant s telephone number, including area code) Liminatus Pharma, Inc.
(SUCCESSOR TO IRIS PARENT HOLDING CORP.) NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1.
As of June 30, 2025, the shares remained unissued and the value of the Company s liability for the unissued shares is $ 7,805,000 , recorded in Deferred underwriting fee common stock payable on the accompanying unaudited condensed consolidated balance sheet.
On July 1, 2025, the Company issued the shares to the underwriters.
The Company has an accumulated deficit of $ 28,879,455 as of June 30, 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →